From the San Antonio Breast Cancer Symposium 2011, more research of combination agents shows positive results.
In Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) which compares treatment with trastuzumab and docetaxel (a standard treatment for metastatic breast cancer) to treatment with pertuzumab (another monoclonal antibody, like trastuzumab) plus the standard treatment drugs, trastuzumab and docetaxel. The findings were significant in extending survival for HER2 positive (metastatic) breast cancer when given as a first line of treatment.
José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im, M.D., Roberto Hegg, M.D., Young-Hyuck Im, M.D., Laslo Roman, M.D., José Luiz Pedrini, M.D., Tadeusz Pienkowski, M.D., Adam Knott, Ph.D., Emma Clark, M.Sc., Mark C. Benyunes, M.D., Graham Ross, F.F.P.M., and Sandra M. Swain, M.D. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. In NEJM 10.1056/NEJMoa1113216 12/7/11
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.